<?xml version="1.0" encoding="UTF-8"?>
<p>Since RRV has been a public health issue for some time now in Australia, vaccine research there has led to several candidates in preclinical studies [
 <xref rid="B231-microorganisms-07-00133" ref-type="bibr">231</xref>,
 <xref rid="B232-microorganisms-07-00133" ref-type="bibr">232</xref>,
 <xref rid="B233-microorganisms-07-00133" ref-type="bibr">233</xref>,
 <xref rid="B234-microorganisms-07-00133" ref-type="bibr">234</xref>], and formalin-inactivated vaccines have successfully passed Phase I, II, and III clinical trials [
 <xref rid="B235-microorganisms-07-00133" ref-type="bibr">235</xref>,
 <xref rid="B236-microorganisms-07-00133" ref-type="bibr">236</xref>]. However, this vaccine is not commercialized, and no RRV vaccine is currently available, highlighting the importance of public/private partnerships to invest in vaccine licensure [
 <xref rid="B237-microorganisms-07-00133" ref-type="bibr">237</xref>].
</p>
